康缘药业
(600557)
| 流通市值：76.36亿 | | | 总市值：76.80亿 |
| 流通股本：5.78亿 | | | 总股本：5.82亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 1,816,857,563.46 | 2,072,277,809.7 | 2,046,174,149.11 | 1,969,272,883.32 |
| 应收票据及应收账款 | 652,710,094.78 | 654,057,500.26 | 695,435,384.39 | 653,766,073.68 |
| 应收账款 | 652,710,094.78 | 654,057,500.26 | 695,435,384.39 | 653,766,073.68 |
| 应收款项融资 | 335,483,569.74 | 334,485,002.87 | 537,032,379.23 | 442,229,504.99 |
| 预付款项 | 44,363,418.68 | 41,925,235.1 | 25,425,535.39 | 28,626,350.98 |
| 其他应收款合计 | 2,842,561.9 | 12,055,048.14 | 13,735,844.26 | 5,315,921.09 |
| 存货 | 546,132,223.92 | 503,529,046.01 | 395,815,182.73 | 350,108,245.14 |
| 其他流动资产 | 6,681,775.79 | 72,206,990.79 | 58,585,240.58 | 73,361,887.19 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 3,730,071,208.27 | 3,900,536,632.87 | 4,222,203,715.69 | 4,049,719,426.38 |
| 非流动资产: | | | | |
| 长期股权投资 | 4,114,497.17 | 4,114,497.17 | 4,109,073.55 | 4,109,073.55 |
| 其他非流动金融资产 | 11,210,107.4 | 11,210,107.4 | 11,210,107.4 | 11,210,107.4 |
| 固定资产 | 2,266,913,709.32 | 2,216,612,851.7 | 2,243,783,439.56 | 2,280,740,570.47 |
| 在建工程 | 318,779,434.99 | 283,845,544.57 | 254,922,876.61 | 227,250,218.26 |
| 无形资产 | 170,354,732.17 | 176,823,021.73 | 190,305,473.33 | 197,380,959.08 |
| 开发支出 | 181,500,752.87 | 177,592,549.86 | 172,766,086.8 | 171,701,113.32 |
| 商誉 | 58,988,858.14 | 58,988,858.14 | 58,988,858.14 | 58,988,858.14 |
| 长期待摊费用 | 12,066,595.33 | 12,845,479.9 | 13,624,364.49 | 14,403,249.06 |
| 递延所得税资产 | 43,037,864.13 | 47,122,929.59 | 50,609,287.5 | 46,222,809.14 |
| 其他非流动资产 | 105,701,791.85 | 164,555,125.94 | 157,447,890.13 | 55,595,282.72 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 3,172,668,343.37 | 3,153,710,966 | 3,157,767,457.51 | 3,067,602,241.14 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 6,902,739,551.64 | 7,054,247,598.87 | 7,379,971,173.2 | 7,117,321,667.52 |
| 流动负债: | | | | |
| 应付票据及应付账款 | 145,272,571.69 | 230,926,714.92 | 253,754,564.94 | 228,418,638.9 |
| 应付账款 | 145,272,571.69 | 230,926,714.92 | 253,754,564.94 | 228,418,638.9 |
| 合同负债 | 15,610,563.69 | 18,553,584.87 | 16,097,493.32 | 25,165,640.9 |
| 应付职工薪酬 | 18,082,362.06 | 12,486,551.7 | 8,002,074.65 | 25,726,012.38 |
| 应交税费 | 75,789,914.18 | 52,899,975.06 | 59,581,584.51 | 70,666,290.59 |
| 其他应付款合计 | 1,179,373,526.81 | 1,243,042,997.71 | 1,374,595,271.56 | 1,238,903,144.53 |
| 其他流动负债 | 2,022,985.6 | 2,396,945.14 | 2,085,531.05 | 3,257,247.16 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 1,436,151,924.03 | 1,560,306,769.4 | 1,714,116,520.03 | 1,608,688,119.36 |
| 非流动负债: | | | | |
| 长期应付款 | 1,925,490 | 1,925,490 | 1,925,490 | 1,925,490 |
| 递延收益 | 128,918,547.37 | 156,508,335.2 | 154,570,746.01 | 126,155,318.28 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 130,844,037.37 | 158,433,825.2 | 156,496,236.01 | 128,080,808.28 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 1,566,995,961.4 | 1,718,740,594.6 | 1,870,612,756.04 | 1,736,768,927.64 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 581,797,452 | 581,797,452 | 584,748,452 | 584,748,452 |
| 资本公积 | 92,956,075.65 | 92,956,075.65 | 111,793,377.69 | 111,793,377.69 |
| 减:库存股 | 210,094,122.29 | 120,002,291.37 | 62,255,152 | 48,135,010 |
| 盈余公积 | 292,813,413.08 | 292,813,413.08 | 292,813,413.08 | 292,813,413.08 |
| 未分配利润 | 4,392,678,207.64 | 4,300,956,522.94 | 4,399,621,756.7 | 4,251,576,797.98 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 5,150,151,026.08 | 5,148,521,172.3 | 5,326,721,847.47 | 5,192,797,030.75 |
| 少数股东权益 | 185,592,564.16 | 186,985,831.97 | 182,636,569.69 | 187,755,709.13 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 5,335,743,590.24 | 5,335,507,004.27 | 5,509,358,417.16 | 5,380,552,739.88 |
| 负债和股东权益合计 | 6,902,739,551.64 | 7,054,247,598.87 | 7,379,971,173.2 | 7,117,321,667.52 |
| 公告日期 | 2024-10-31 | 2024-07-27 | 2024-04-13 | 2024-03-11 |
| 审计意见(境内) | | | | 标准无保留意见 |